NZ587362A - 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists - Google Patents

3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists

Info

Publication number
NZ587362A
NZ587362A NZ587362A NZ58736209A NZ587362A NZ 587362 A NZ587362 A NZ 587362A NZ 587362 A NZ587362 A NZ 587362A NZ 58736209 A NZ58736209 A NZ 58736209A NZ 587362 A NZ587362 A NZ 587362A
Authority
NZ
New Zealand
Prior art keywords
optionally substituted
group
methyl
oxo
diazepan
Prior art date
Application number
NZ587362A
Other languages
English (en)
Inventor
Mark Arnold Thomas Blaskovich
Peter Joseph Cassidy
Original Assignee
Mimetica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mimetica Pty Ltd filed Critical Mimetica Pty Ltd
Publication of NZ587362A publication Critical patent/NZ587362A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ587362A 2008-02-29 2009-02-27 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists NZ587362A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3289808P 2008-02-29 2008-02-29
PCT/AU2009/000232 WO2009105825A1 (en) 2008-02-29 2009-02-27 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists

Publications (1)

Publication Number Publication Date
NZ587362A true NZ587362A (en) 2012-06-29

Family

ID=41015442

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ587362A NZ587362A (en) 2008-02-29 2009-02-27 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists

Country Status (14)

Country Link
US (1) US8440653B2 (enExample)
EP (1) EP2257533B1 (enExample)
JP (1) JP5503559B2 (enExample)
KR (1) KR101620116B1 (enExample)
CN (1) CN102007106B (enExample)
AU (1) AU2009219108B2 (enExample)
BR (1) BRPI0907898B8 (enExample)
CA (1) CA2716256C (enExample)
ES (1) ES2439964T3 (enExample)
IL (1) IL207701A (enExample)
MX (1) MX2010009486A (enExample)
NZ (1) NZ587362A (enExample)
RU (1) RU2524245C2 (enExample)
WO (1) WO2009105825A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009219107B2 (en) * 2008-02-29 2013-11-21 Marp Therapeutics Pty Ltd Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
WO2016149628A1 (en) * 2015-03-19 2016-09-22 Chembridge Corporation Tgr5 agonists
US11485725B2 (en) 2017-12-15 2022-11-01 Auransa Inc. Derivatives of piperlongumine and uses thereof
CN116262115B (zh) * 2021-12-15 2026-02-24 深圳先进技术研究院 释放氨基酸及其衍生物类药物的医用材料及其应用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP254898A0 (en) * 1998-03-24 1998-04-23 University Of Queensland, The Peptide turn mimetics
DE60114413T2 (de) * 2000-05-25 2006-07-27 F. Hoffmann-La Roche Ag Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
WO2003013571A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US6916812B2 (en) 2001-10-09 2005-07-12 Bristol-Myers Squibb Company Alpha-aminoamide derivatives as melanocortin agonists
WO2003068738A1 (en) 2002-02-11 2003-08-21 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
WO2008017852A1 (en) 2006-08-11 2008-02-14 Palatin Technologies, Inc. Diamine-containing, tetra- substituted piperazine compounds as melanocortin receptor modulators
AU2009219107B2 (en) * 2008-02-29 2013-11-21 Marp Therapeutics Pty Ltd Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor

Also Published As

Publication number Publication date
HK1149255A1 (en) 2011-09-30
US8440653B2 (en) 2013-05-14
MX2010009486A (es) 2011-02-22
KR101620116B1 (ko) 2016-05-12
CN102007106A (zh) 2011-04-06
BRPI0907898B8 (pt) 2021-05-25
CN102007106B (zh) 2014-09-03
BRPI0907898B1 (pt) 2020-09-29
EP2257533B1 (en) 2013-09-18
AU2009219108A1 (en) 2009-09-03
US20110059952A1 (en) 2011-03-10
JP2011514339A (ja) 2011-05-06
KR20100126440A (ko) 2010-12-01
EP2257533A1 (en) 2010-12-08
WO2009105825A1 (en) 2009-09-03
BRPI0907898A2 (pt) 2018-05-22
CA2716256C (en) 2016-08-23
IL207701A (en) 2017-04-30
RU2010137033A (ru) 2012-04-10
CA2716256A1 (en) 2009-09-03
JP5503559B2 (ja) 2014-05-28
AU2009219108B2 (en) 2013-11-21
EP2257533A4 (en) 2011-05-11
RU2524245C2 (ru) 2014-07-27
ES2439964T3 (es) 2014-01-27
IL207701A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
CA2716316C (en) Methods of modulating the activity of the mc5 receptor and treatment of conditions related to this receptor
EP2257534B1 (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
AU2009219108B2 (en) 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists
US9340517B2 (en) Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
US8343958B2 (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists
HK1149255B (en) 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists
HK1148730B (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
HK1149187A (en) Compounds for use in the treatment of acne, seborrhoea and sebhorroeic dermatitis, or for reducing sebum secretion
HK1149187B (en) Compounds for use in the treatment of acne, seborrhoea and sebhorroeic dermatitis, or for reducing sebum secretion

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 FEB 2016 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20130108

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 FEB 2017 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20160223

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 FEB 2018 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20170209

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 FEB 2019 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20180220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 FEB 2020 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20190227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 FEB 2021 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20200212

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 FEB 2022 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20210226

LAPS Patent lapsed